Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Breast Cancer - HER2 Positive Clinical Trials

A listing of Breast Cancer - HER2 Positive medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (19) clinical trials

We are studying whether aspirin can prevent breast cancer from coming back or prevent the spread of breast cancer. Studies have linked aspirin with a lower risk of death from cancer.

Phase N/A

microRNA of Human Epidermal Growth Factor Receptor 2 HER2 Positive Patient Treated With Herceptin

This projective observational study is planned to enroll more than 300 advanced breast cancer patients, who were proved as Her-2 positive using fluorescence in situ hybridization (FISH) and / or immunohistochemistry, and 100 healthy donors as control. Before treatment, the plasma microRNA will be collected and detected by microRNA extraction ...

Phase N/A

Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients

Breast cancer is the commonest cancer in women worldwide with an estimated 1.4 million new diagnoses in 2008 and 1.6 million cases estimated for 2015. In 2008 breast cancer was responsible for approximately 23% of all new cancer diagnoses in women. It is also the commonest cause of cancer deaths ...

Phase N/A

Identification of Early Markers of Response and Resistance to Trastuzumab

The study is a single arm prospective study, aiming at identifying biomarkers of early response to trastuzumab. It is a prognostic factor study recruiting all consecutive cases of HER-2 positive breast cancer eligible for a pre-operative treatment by trastuzumab, followed by breast conserving surgery. The investigators will study the association ...

Phase N/A

Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy

PRIMARY OBJECTIVES: I. Identify novel genomic variants and pathways associated with early progression (progression within 12 months) among women with advanced hormone positive breast cancer treated with palbociclib and endocrine therapy. SECONDARY OBJECTIVES: I. To assess whether time to progression differs with respect to SNAIL expression and other markers of ...

Phase N/A

CharactHer. ICORG 12-09 V3

Type of Study: Translational This is a pilot retrospective laboratory-based cohort study. Eligible patients will be identified at each one of the participating institutions by a systematic cross-matching of the datasets of Medical Oncology, Pathology and Pharmacy Departments. Patient Population: Cohort 1: TNM stage II-IV breast cancer patients with highly ...

Phase N/A

Exosomal and Free Extracellular RNAs and Proteins as Predictive. ICORG 10-15 V2

This is a translational pilot study, involving two patient cohorts, designed to identify predictive biomarkers for HER2 targeted therapy, which will be validated in a larger future study. Cohort 1: 300 newly diagnosed (including metastatic) HER2 positive breast cancer patients. Cohort 2: 30 newly diagnosed HER2 negative breast cancer patients. ...

Phase N/A

PRospective Study to Measure the Impact of MammaPrint on Adjuvant Treatment in Hormone Receptor-positive HER2-negative Breast Cancer Patients (PRIMe)

PRIMe is a prospective, case-only trial designed to measure the impact of MammaPrint on physician chemotherapy intention in the two discordant groups (ET/POOR, CT/GOOD) in stage 1 and 2 HR-positive HER2-negative breast cancer patients. The design also provides for assessment of several important secondary indicators. Eligible patients will have their ...

Phase N/A

Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases Which Are Amenable to HER2 Targeted Therapy?

Some breast cancer cells make a protein called Human Epidermal Growth factor receptor 2 (HER2). Patients with HER2 positive (HER2+) breast cancer receive medicine that attacks HER2, which helps these patients live longer. Some HER2 negative (HER2-) breast cancer patients also benefit from medicines that attack HER2, but we do ...

Phase N/A